A5069865054- Diabetes Treatment and Management
- Chronic Kidney Disease and Diabetes
- Dialysis and Renal Disease Management
- Pancreatic function and diabetes
- Diabetes Management and Research
- Blood Pressure and Hypertension Studies
- Potassium and Related Disorders
- Renal Diseases and Glomerulopathies
- Parathyroid Disorders and Treatments
- Erythropoietin and Anemia Treatment
- Metabolism, Diabetes, and Cancer
- Lipoproteins and Cardiovascular Health
- Health Systems, Economic Evaluations, Quality of Life
- Iron Metabolism and Disorders
- Bipolar Disorder and Treatment
- Hormonal Regulation and Hypertension
- Renal and Vascular Pathologies
- Neurological and metabolic disorders
- Heart Failure Treatment and Management
- Medication Adherence and Compliance
- Renal Transplantation Outcomes and Treatments
- Chronic Disease Management Strategies
- Pharmacology and Obesity Treatment
- Vitamin D Research Studies
- Muscle and Compartmental Disorders
University College London
2016-2025
The George Institute for Global Health
2019-2024
Roland Hill (United Kingdom)
2002-2024
The Royal Free Hospital
2008-2024
UNSW Sydney
2019-2024
Royal Free London NHS Foundation Trust
2012-2024
Newcastle University
2024
Newcastle upon Tyne Hospitals NHS Foundation Trust
2016-2024
Hofstra University
2024
VCU Massey Comprehensive Cancer Center
2024
Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials inhibitors sodium–glucose cotransporter (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type diabetes.
Patients with chronic kidney disease have a high risk of adverse and cardiovascular outcomes. The effect dapagliflozin in patients disease, or without type 2 diabetes, is not known.
Some propose using phosphate binders in the CKD population given association between higher levels of phosphorus and mortality, but their safety efficacy this are not well understood. Here, we aimed to determine effects on parameters mineral metabolism vascular calcification among patients with moderate advanced CKD. We randomly assigned 148 estimated GFR=20-45 ml/min per 1.73 m(2) calcium acetate, lanthanum carbonate, sevelamer or placebo. The primary endpoint was change mean serum from...
A number of US observational studies reported an increased mortality risk with higher intact parathyroid hormone (iPTH), calcium and/or phosphate. The existence such a link in European haemodialysis population was explored as part the Analysing Data, Recognising Excellence and Optimising Outcomes (ARO) Chronic Kidney Disease (CKD) Research Initiative.The association between markers mineral bone disease clinical outcomes examined 7970 patients treated Fresenius Medical Care facilities over...
<h3>Importance</h3> Guidelines recommend corticosteroids in patients with IgA nephropathy and persistent proteinuria, but the effects remain uncertain. <h3>Objective</h3> To evaluate efficacy safety of at risk progression. <h3>Design, Setting, Participants</h3> The Therapeutic Evaluation Steroids Nephropathy Global (TESTING) study was a multicenter, double-blind, randomized clinical trial designed to recruit 750 participants (proteinuria greater than 1 g/d estimated glomerular filtration...
Before the introduction of erythropoiesis-stimulating agents (ESAs) in 1989, repeated transfusions given to patients with end-stage renal disease caused iron overload, and need for supplemental was rare. However, widespread ESAs, it recognized that necessary optimize hemoglobin response allow reduction ESA dose economic reasons recent concerns about safety. Iron supplementation also found be more efficacious via intravenous compared oral administration, use has escalated years. The safety...
Intravenous iron is a standard treatment for patients undergoing hemodialysis, but comparative data regarding clinically effective regimens are limited.In multicenter, open-label trial with blinded end-point evaluation, we randomly assigned adults maintenance hemodialysis to receive either high-dose sucrose, administered intravenously in proactive fashion (400 mg monthly, unless the ferritin concentration was >700 μg per liter or transferrin saturation ≥40%), low-dose reactive (0 400 of <200...
The incidence and prevalence of heart failure (HF) chronic kidney disease (CKD) are increasing, as such a better understanding the interface between both conditions is imperative for developing optimal strategies their detection, prevention, diagnosis, management. To this end, Kidney Disease: Improving Global Outcomes (KDIGO) convened an international, multidisciplinary Controversies Conference titled Heart Failure in CKD. Breakout group discussions included (i) HF with preserved ejection...
Immunoglobulin A (IgA) nephropathy is a common form of glomerulonephritis, which despite use renin-angiotensin-aldosterone-system blockers and immunosuppressants, often progresses to kidney failure. In the Dapagliflozin Prevention Adverse Outcomes in Chronic Kidney Disease trial, dapagliflozin reduced risk failure prolonged survival participants with chronic disease without type 2 diabetes, including those IgA nephropathy. Participants estimated glomerular filtration rate (eGFR) 25-75...
Patients with kidney disease have disordered bone and mineral metabolism, including elevated serum concentrations of fibroblast growth factor-23 (FGF23). These are associated cardiovascular all-cause mortality. The objective was to determine the effects calcimimetic cinacalcet (versus placebo) on reducing FGF23 whether changes in death events.This a secondary analysis randomized clinical trial comparing placebo addition conventional therapy (phosphate binders/vitamin D) patients receiving...
Background: Canagliflozin reduces the risk of kidney failure in patients with type 2 diabetes mellitus and chronic disease, but effects on specific cardiovascular outcomes are uncertain, as people without previous disease (primary prevention). Methods: In CREDENCE (Canagliflozin Renal Events Diabetes With Established Nephropathy Clinical Evaluation), 4401 participants were randomly assigned to canagliflozin or placebo a background optimized standard care. Results: Primary prevention (n=2181,...